Drexel Symposium Highlights Injectable Self-Healing Hydrogels for Therapeutic Treg Induction and Strategies to Mitigate LNP-Induced Inflammation

August 9, 2026

Drexel University USA

Overview

A symposium at Drexel University showcased the development of injectable self-healing granular hydrogels optimized for inducing therapeutic regulatory T cells (Tregs), with modified B7x demonstrating dose-dependent Treg expansion in vitro. The event also emphasized the critical need to manage potential inflammatory responses caused by lipid nanoparticles (LNPs) to broaden their application in inflammation-related diseases. These advancements represent significant progress in immunotherapy and nanomedicine, offering new therapeutic avenues and addressing key challenges in immune modulation.

In Depth

Key Findings

At the Immune Modulation and Engineering Symposium hosted by Drexel University, researchers presented advances in developing injectable, self-healing granular hydrogels optimized for the induction of therapeutic regulatory T cells (Tregs). In vitro studies revealed that modified B7x embedded within these hydrogels dose-dependently increased Treg populations. Furthermore, the symposium highlighted the imperative of effectively managing inflammation potentially induced by lipid nanoparticles (LNPs)—highly efficient carriers for intracellular mRNA delivery—to expand their therapeutic utility in a wider range of inflammation-related diseases.

Technical / Clinical Details

The presented injectable hydrogels are engineered to induce Treg cells in vivo, with their self-healing and granular properties promising stable and uniform distribution within tissues post-injection. Modified B7x molecules incorporated into the hydrogel promote the proliferation and activation of Treg cells through specific signaling pathways, thereby inducing immune tolerance. In vitro experiments confirmed a dose-proportional increase in Treg cell populations with increasing B7x concentration, suggesting potential applications in suppressing autoimmune diseases and transplant rejection.

While LNPs have demonstrated widespread efficacy, notably in COVID-19 vaccines, they have also been reported to induce inflammatory responses. The symposium addressed the importance of elucidating the mechanisms of LNP-induced inflammation and developing nanotechnological approaches to mitigate it, such as LNP surface modifications or novel lipid compositions. Successful control of these inflammatory responses would significantly expand the potential of LNPs as delivery systems for mRNA and siRNA-based therapeutics in a broader spectrum of inflammation-related conditions, including autoimmune diseases, allergies, and cancer immunotherapy.

Treg-Inducing Hydrogels: Self-healing granular hydrogels with modified B7x demonstrate dose-dependent increases in Treg cell populations.
LNP Challenges and Solutions: Strategies are being developed to manage LNP-induced inflammation to broaden applications in inflammation-related diseases.

Background & Context

Advances in immunotherapy represent one of the most promising fields in modern medicine. Specifically, technologies that control Treg cells offer a potentially revolutionary therapeutic approach for diseases involving excessive immune responses, such as autoimmune disorders, organ transplant rejection, and allergies. Current treatments often involve systemic immunosuppression with high risks of side effects. Nanomaterials that locally or selectively induce Tregs could provide safer and more effective alternatives. Moreover, mRNA therapeutics are a leading next-generation modality, and ensuring both the safety and efficacy of their LNP delivery systems is crucial for future drug development.

Strategic Significance & Outlook

These research efforts have the potential to usher in a paradigm shift in the treatment of immune-mediated diseases. Treg-inducing hydrogels open new avenues for inducing disease-specific immune tolerance, offering less toxic therapies for autoimmune conditions and transplant medicine. For LNPs, the focus will accelerate the development of next-generation systems that enable efficient nucleic acid delivery while minimizing inflammation. These nanotechnology-based approaches are also expected to contribute significantly to personalized medicine, eventually leading to widespread application as precision therapeutics for a diverse array of diseases. Pharmaceutical and biotechnology companies are likely to accelerate partnerships and investments to translate these technologies into clinical applications.

Source: https://drexel.edu/biomed/research-and-design/overview/IMES2024%20abstracts/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.